Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.
Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...
PHILADELPHIA — The investigational drug verekitug improved sinonasal symptoms, reduced nasal polyp size, and reduced the need for nasal polyp surgery in people with chronic rhinosinusitis with nasal ...
NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released The New Growth Frontier. This new analysis, ...
NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released The New Growth Frontier. This new analysis, produced in collaboration with ...
Follow this Marathon quest walkthrough to help you complete every step of the Data Reconstruction Priority Contract for ...
Glycosylation research is steadily emerging as a critical area in the field of tumor immunology, offering fresh insights into how cancers subvert immune ...
Researchers at the University of California San Diego and collaborators have discovered a new way to help the immune system fight ovarian cancer by changing how tumors communicate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results